Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 2/20 | 0.50 |
| ▸ | IDO2 | Q6ZQW0 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.44 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.44 |
| ▸ | MAT2A | P31153 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23045334 | 1.00 | TDO2 (0.50) | TDO2IDO2USP2POLBIDO1 | |
| SCHEMBL23958194 | 0.93 | TDO2 (0.46) | TDO2IDO2USP2POLBIDO1 | |
| SCHEMBL29623172 | 0.90 | TDO2 (0.44) | TDO2IDO2POLBIDO1HTR7 | |
| SCHEMBL24090107 | 0.90 | TDO2 (0.44) | TDO2IDO2POLBIDO1HTR7 | |
| SCHEMBL24090095 | 0.90 | PIK3CD (0.50) | TDO2IDO2USP2IDO1PIK3CD | |
| SCHEMBL29738614 | 0.90 | PIK3CD (0.46) | TDO2IDO2POLBIDO1PIK3CD | |
| SCHEMBL23958265 | 0.90 | PIK3CD (0.46) | TDO2IDO2POLBIDO1PIK3CD | |
| SCHEMBL23064665 | 0.88 | TDO2 (0.45) | TDO2IDO2USP2POLBIDO1 | |
| SCHEMBL23958242 | 0.88 | TDO2 (0.45) | TDO2IDO2POLBIDO1HTR7 | |
| SCHEMBL30025705 | 0.88 | TDO2 (0.45) | TDO2IDO2POLBIDO1HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114650986-A | 2-aminoquinazolinone derivatives | 住友制药株式会社 | 2022-06-21 | — | — | CN | claimed |
| CN-114650986-A | 2-aminoquinazolinone derivatives | 住友制药株式会社 | 2022-06-21 | — | — | CN | disclosed |
| US-11352366-B2 | 2-aminoquinazolinone derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352366-B2 | 2-aminoquinazolinone derivative | CNKSR1, HAX1, SLC26A3 | TDO2 1774/4885IDO2 416/4885USP2 3548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.